Compound PR-619 Restores Cisplatin Sensitivity in Liver Cancer
The deubiquitinating enzyme inhibitor destabilizes the G9a protein to enhance chemotherapy efficacy in laboratory studies.
Updated on Oct. 27, 2026 in Cancer
Experimental research reveals that the chemical compound PR-619 restores sensitivity to cisplatin in hepatocellular carcinoma cell lines. The treatment works by accelerating the degradation of the G9a protein, which is known to blunt the response to platinum-based chemotherapy.
Why it matters
High G9a expression is linked to chemotherapy resistance in liver cancer, preventing cancer cells from undergoing programmed cell death. Targeting this pathway could improve treatment outcomes for patients who do not respond to standard platinum-based regimens.
PR-619 treatment reduces H3K9 dimethylation marks by accelerating polyubiquitination and subsequent proteasomal degradation of the G9a protein. Researchers confirmed this effect in HuH7 and SNU387 liver cancer cell lines.
The details
The study demonstrates that G9a depletion triggers apoptotic signaling, including the cleavage of PARP and caspase-3, in cancer cells. When used as a broad-spectrum deubiquitinating enzyme inhibitor, PR-619 effectively destabilizes G9a, rendering the carcinoma cells susceptible to cisplatin again.
Timeline
Researchers conducted the experimental application of PR-619 to hepatocellular carcinoma cell lines in an in vitro laboratory setting.
The Big Picture
This discovery shifts the understanding of chemotherapy resistance by targeting the epigenetic regulator G9a rather than focusing on traditional drug efflux pumps. The findings suggest a paradigm shift in how oncologists might address blunted apoptotic responses in solid tumors.
This laboratory discovery offers a potential pathway for future clinical treatments aimed at patients whose liver cancer fails to respond to standard platinum-based chemotherapy. While the findings are limited to cell models, they highlight a target that could eventually influence personalized oncology and medication selection.
The takeaway
Targeting G9a degradation presents a promising strategy for overcoming cellular chemotherapy resistance. Researchers must now focus on validating these laboratory results in living systems to determine the feasibility of future clinical application.
Further reading
For more on the current landscape of oncology research, see our coverage of Cancer.
Source note: This article includes information reported by Alwasat-ye.
